| An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis N Çakici, NJM Van Beveren, G Judge-Hundal, MM Koola, IEC Sommer Psychological medicine 49 (14), 2307-2319, 2019 | 194 | 2019 |
| Systematic review of treatments for diabetic peripheral neuropathy N Çakici, TM Fakkel, JW Van Neck, AP Verhagen, JH Coert Diabetic medicine 33 (11), 1466-1476, 2016 | 177 | 2016 |
| Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis N Çakici, AL Sutterland, BWJH Penninx, VA Dalm, L de Haan, ... Brain, behavior, and immunity 88, 547-558, 2020 | 124 | 2020 |
| Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: a cross-disorder proteomics analysis N Çakici, M Bot, F Lamers, T Janssen, PJ van der Spek, L de Haan, ... European Neuropsychopharmacology 29 (7), 835-846, 2019 | 33 | 2019 |
| Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a … N Çakici, AL Sutterland, BWJH Penninx, L De Haan, NJM Van Beveren Psychological Medicine 51 (4), 538-549, 2021 | 30 | 2021 |
| Risk factors for developing diabetic peripheral neuropathy: A meta-analysis TM Fakkel, N Çakici, JH Coert, AP Verhagen, WM Bramer, JW van Neck SN Comprehensive Clinical Medicine 2, 1853-1864, 2020 | 6 | 2020 |
| Potential Benefits of Ketone Therapy as a Novel Immunometabolic Treatment for Schizophrenia K Huizer, S Soni, MA Schmidt, N Cakici, L de Haan, JRB Dyck, ... bioRxiv, 2024.05. 23.595523, 2024 | | 2024 |
| Cross-sectional association between metabolic parameters and psychotic-like experiences in a population-based sample of middle-aged and elderly individuals N Çakici, NH Grootendorst-van Mil, SJ Roza, H Tiemeier, L de Haan, ... Schizophrenia Research 261, 145-151, 2023 | | 2023 |
| Predictive biomarkers for negative symptoms in schizophrenia N Cakici, L De Haan, N Van Beveren European Psychiatry 64 (S1), S132-S133, 2021 | | 2021 |
| Anti-inflammatory Agents for Patients with Schizophrenia NJM van Beveren, N Çakici, IE Sommer Immuno-Psychiatry: Facts and Prospects, 365-388, 2021 | | 2021 |
| Reply to interleukin-6 in schizophrenia: Cause of death matters N Çakici, AL Sutterland, BWJH Penninx, L de Haan, NJM van Beveren Brain, behavior, and immunity 90, 383-384, 2020 | | 2020 |
| O10. 7. SIMILARLY ALTERED PROTEIN MARKERS IN DRUG-NAïVE FIRST-EPISODE PATIENTS WITH SCHIZOPHRENIA OR MAJOR DEPRESSIVE DISORDER. A META-ANALYSIS N Çakici, AL Sutterland, JH Penninx, L Haan, NJ van Beveren Schizophrenia Bulletin 45 (Supplement_2), S192-S193, 2019 | | 2019 |
| T68. SUBCLINICAL PSYCHOTIC PHENOMENA ARE ASSOCIATED WITH MARKERS OF AN ALTERED METABOLISM IN A LARGE COMMUNITY SAMPLE N Çakici, NH van Mill, SJ Roza, LD Haan, AI Luik, NJ van Beveren Schizophrenia Bulletin 45 (Supplement_2), S230-S231, 2019 | | 2019 |
